-
Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
Spencer K, Cowans NJ, Nicolaides KH.
Prenat Diagn 2008;28:7-10. -
Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:871-6. -
Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation.
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH.
Prenat Diagn 2008;28:1110-5. -
Urine albumin concentration and albumin-to-creatinine ratio at 11(+0) to 13(+6) weeks in the prediction of pre-eclampsia.
Poon LC, Kametas N, Bonino S, Vercellotti E, Nicolaides KH.
BJOG 2008;115:866-73. -
Physiological distribution of placental growth factor and soluble Flt-1 in early pregnancy.
Makrydimas G, Sotiriadis A, Savvidou MD, Spencer K, Nicolaides KH.
Prenat Diagn 2008;28:175-9. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:488-92. -
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:618-24. -
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:493-50. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75. -
Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia.
Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:732-9. -
Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
Noble PL, Abraha HD, Snijders RJ, Sherwood R, Nicolaides KH.
Ultrasound Obstet Gynecol 1995;6:390-5. -
Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.
Brizot ML, Snijders RJ, Butler J, Bersinger NA, Nicolaides KH.
Br J Obstet Gynaecol 1995;102:127-32. -
Placental expression of alpha and beta subunits of human chorionic gonadotrophin in early pregnancies with Down's syndrome.
Brizot ML, Jauniaux E, Mckie AT, Farzaneh F, Nicolaides KH.
Hum Reprod 1995;10:2506-9. -
Fetal and maternal hCG concentration in aneuploid pregnancies.
Abbas A, Chard T, Nicolaides KH.
Br J Obstet Gynaecol 1995;102:561-3.